StockNews.AI

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

StockNews.AI • 1 minute

N/A
High Materiality8/10

Information

HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a...

Original source

AI Summary

Plus Therapeutics, Inc. (PSTV) has announced a public offering priced at $0.38 per unit, projected to raise about $15 million in gross proceeds. The funding aims to bolster working capital and support the company's strategic initiatives in CNS cancer therapies, thus potentially enhancing financial stability.

Sentiment Rationale

Historically, such capital raises can provide necessary liquidity and investor confidence. Companies with clear end-use of proceeds often see a positive market response, as it directly influences future growth prospects.

Trading Thesis

PSTV is a buy; expected cash infusion may support growth initiatives in CNS cancers.

Market-Moving

  • Public offering pricing indicates investors’ willingness to support PSTV's growth.
  • The anticipated $15 million may be critical for further development.
  • Warrants provide additional upside potential for investors.
  • Market reaction will depend on the successful execution of the offering.

Key Facts

  • PSTV prices public offering at $0.38 per unit, raising approximately $15 million.
  • Offering includes shares and warrants, effective for five years.
  • Proceeds will support working capital and corporate needs.
  • Offering expected to close on January 15, 2026, pending conditions.
  • Underwriter has option for additional shares to cover over-allotments.

Companies Mentioned

  • Lake Street Capital Markets, LLC (N/A): Acting as sole underwriter for the offering.
  • CNSide Diagnostics, LLC (N/A): Subsidiary focused on developing CNS cancer diagnostics.

Corporate Developments

This event falls under Corporate Developments as it involves a capital raise intended to enhance business operations and support clinical programs. Such developments are crucial for funding initiatives in a capital-intensive industry like pharmaceuticals.

Plus Therapeutics (PSTV) Prices $15 Million Public Offering

On January 14, 2026, Plus Therapeutics, Inc. (NASDAQ: PSTV), a Houston-based healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced the pricing of its underwritten public offering. The offering includes 39,473,684 units, each consisting of one share of common stock and one warrant, priced at $0.38 per unit. The anticipated gross proceeds from this offering are approximately $15 million.

Details of the Public Offering

The public offering by Plus Therapeutics will provide gross proceeds of about $15 million, before accounting for underwriting discounts and commissions, as well as other estimated offering expenses. Each warrant included in the offering is immediately exercisable, allowing the holder to purchase one share of common stock at an exercise price of $0.38. These warrants will expire five years from issuance.

Furthermore, the underwriter has a 30-day option to purchase up to an additional 5,921,052 shares of common stock and/or warrants to purchase the same amount, intended to cover over-allotments, if necessary.

Use of Proceeds

The proceeds from this public offering will be allocated towards working capital and general corporate purposes, reinforcing Plus Therapeutics' commitment to advancing its clinical initiatives.

Expected Closing and Underwriter

The public offering is expected to close on January 15, 2026, pending the fulfillment of customary closing conditions. Lake Street Capital Markets, LLC is serving as the sole underwriter for this offering.

Regulatory Filings

A registration statement on Form S-1 relating to the securities offered was filed with the Securities and Exchange Commission (SEC) on January 9, 2026, and was declared effective on January 13, 2026. The preliminary and final prospectus related to the offering can be accessed for free on the SEC's website at www.sec.gov.

Company Overview

Plus Therapeutics, Inc. is dedicated to developing targeted radiotherapeutics for challenging CNS tumors. The company employs innovative methods, including image-guided local beta radiation and targeted drug delivery, to create a robust pipeline of product candidates. They focus on primary areas such as leptomeningeal metastases (LM) and recurrent glioblastoma (GBM).

Additionally, Plus Therapeutics oversees a subsidiary, CNSide Diagnostics, which specializes in laboratory-developed tests, specifically the CNSide® CSF Assay Platform designed for improved management of leptomeningeal metastases through the analysis of cerebrospinal fluid.

Forward-Looking Statements

This press release may contain forward-looking statements as defined under U.S. securities laws. These statements reflect the Company’s expectations concerning future events, involving assumptions and assessments based on historical trends and current conditions. However, actual outcomes may differ significantly due to various risks and uncertainties.

Key factors that could influence these statements include the Company’s ability to complete the offering, successfully raise sufficient capital, and continue its clinical studies. As with all forward-looking information, stakeholders should consider potential risks before making investment decisions.

Related News